All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

pipeline-prospector-insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

Country

News Type

Company

Product Type

Deal Size

refresh

Product Type

Companies

Eisai

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

IFT Annual Expo

Participation Not Confirmed

Update your events

Eisai Announces U.S. Availability of DAYVIGO® (lemborexant) CIV, a New Treatment Option for Adults With Insomnia

Contact the Supplier

Lead Product(s): Lemborexant

Therapeutic Area: Sleep Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2020

Details:

In clinical studies, DAYVIGO helped some people with insomnia fall asleep faster and stay asleep longer compared to placebo. The effects of DAYVIGO at first use were generally consistent with later timepoints.